Table 2 Adverse events for each agent
From: Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia
Type of agents | Agents | Adverse events |
|---|---|---|
γ-Secretase inhibitors (GSIs) | MK-0752 | Gastrointestinal toxicity (mainly diarrhea) |
PF-03084014 | Nausea and vomiting | |
BMS-906024 | Tolerable gastrointestinal toxicity | |
MRK-560 | Did not show obvious gastrointestinal pathological changes and thymus T cell development defects | |
ADAM inhibitors | G1254023X | No records of adverse events related to the drug found in the literature |
Monoclonal antibody targeting NOTCH1 | OMP-52M51 | May be resistant to T-ALL of carried two activation mutations of NOTCH1 gene: p.Q1584H and p.L1585P |
mAb604.107 | No records of adverse events related to the drug found in the literature | |
Direct inhibition of NOTCH1 transcription factor complex | SAHM1 | No records of adverse events related to the drug found in the literature |
SERCA inhibitors | Thapsigargicin | Severe dose-limited cardiotoxicit |
JQ-FT | Complex process and poor practicality | |
Clerodane diterpene casearin J (CJ) | No records of adverse events related to the drug found in the literature | |
CAD204520 | No weight loss, no adverse effects on behavior, and no signs of acute cardiotoxicity or gastrointestinal metaplasia |